Canterbury DHB

Context

Management of AML

In This Section

Introduction and Key Questions

Current Trials in AML

Supportive Care

Emergencies in Acute Leukaemia

AML 19

Management of non-trial patients

Management of older patients with Acute Myeloid Leukaemia

Management of Relapse or Refractory Patients

Palliative Care

Introduction and Key Questions

Key Questions:

If suitable for intensive treatment:

The decision regarding trial entry or other treatment is made by the patient and their Consultant.

Current Trials in AML

For current trials in AML, see the Clinical Trials page on the Intranet or phone the Clinical Trials Co-ordinator (ext: 80377).

Supportive Care

This is to some extent individualised depending on the type of treatment the patient is receiving. For example, it will differ during intensive chemotherapy treatment compared to any subsequent allograft procedures if they may be given.

Key Aspects of Supportive Care

Note: PCP is uncommon with current AML treatment schedules, except for those containing fludarabine.

Emergencies in Acute Leukaemia

Complications of acute leukaemia and its treatment are an important cause of mortality and morbidity. They include:

An expert review of managing these conditions was published in 2012. See Zuckerman, T., C. Ganzel, et al. (2012). "How I treat hematologic emergencies in adults with acute leukemia." Blood 120(10): 1993-2002.

About this Canterbury DHB document (4287):

Document Owner:

Ruth Spearing (see Who's Who)

Issue Date:

October 2018

Next Review:

October 2020

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 4287